Latest Financials News

Dataworks Group Limited reported a significant reduction in its half-year loss alongside a major contract extension in Ontario, marking a pivotal shift to positive cash flow.

icetana Limited reports a strong first half of 2026 with recurring revenue up 43%, driven by key partnerships and expanded market reach across APAC and the Middle East.

Delorean Corporation reports a significant half-year loss as it pivots from contractor to bioenergy infrastructure owner, advancing key projects but facing financial covenant breaches.

Coventry Group Ltd posted a modest revenue increase to $187.4 million for the half year ended December 2025, but underlying EBITDA plunged 67.7% amid a statutory net loss of $9.7 million. A strategic review is underway as the company suspends dividends to focus on debt reduction and growth.

Frontier Energy Limited has reported a sharp 71% increase in net loss for the year ended 31 December 2025, with no dividends declared and a slight dip in net tangible assets per share.

Ariadne Australia Ltd reported a modest net profit of $2.8 million for the half-year ended December 2025, underpinned by strong growth in its Orams Group investment and key strategic assets despite foreign exchange headwinds.

GreenHy2 Limited narrowed its net loss by 16% in FY2025, driven by government grants and initial sales of its new sodium-ion batteries. Strategic partnerships and product diversification position the company for growth in renewable energy storage.

Atlas Pearls reports a challenging first half of FY26 with a 27% drop in revenue and a net loss of $5.2 million, driven by weaker market demand and a shift towards lower-grade pearl sales.

Infotrust Ltd reported a significant $16.5 million half-year loss driven by a $15.6 million impairment on its Cloud and Communications segment, which it plans to divest for up to $50 million. The move refocuses the company on its core Cyber Security business amid steady revenue growth.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

DorsaVi Limited reported a steep increase in its half-year loss to $3.6 million, driven by declining revenues and a sharp rise in operating costs, despite raising over $5 million in fresh capital.

Patrys Limited reported a near doubling of its half-year loss to $3.02 million, driven by restructuring and a strategic pivot including the acquisition of Reliis Pty Ltd. The company is advancing a dual-platform biotech strategy combining a clinical-stage CNS asset with its proprietary antibody platform.